Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Area of Science:

• Neuroimmunology
• Clinical Neurology
• Pharmacology

Background:

• Relapsing-remitting multiple sclerosis (RRMS) often requires combination therapy for persistent disease activity despite first-line treatments.
• Intramuscular interferon beta-1a (IM IFNbeta-1a) is a standard monotherapy, but some RRMS patients exhibit continued disease activity.
• Investigator-initiated trials are crucial for exploring novel therapeutic strategies in MS.

Purpose of the Study:

• To review the rationale, design, and baseline data of the Avonex Combination Trial (ACT).
• To assess the combination of IM IFNbeta-1a with methotrexate (MTX) and/or IV methylprednisolone (IVMP) in RRMS patients.
• To evaluate combination therapy in patients with ongoing disease activity despite IM IFNbeta-1a monotherapy.

Main Methods:

• The ACT study enrolled 313 RRMS patients with Expanded Disability Status Scale scores of 0-5.5.
• Participants continued IM IFNbeta-1a and were randomized in a 2x2 factorial design to receive MTX and/or IVMP.
• Eligibility required at least one relapse or gadolinium-enhancing MRI lesion in the preceding year while on IM IFNbeta-1a monotherapy.

Main Results:

• Baseline characteristics were typical for RRMS, with 86.9% qualifying due to a clinical relapse.
• At study entry, 21.4% of patients had enhancing MRI lesions and 5.1% had anti-IFNbeta neutralizing antibodies.
• The study's operational and management structures were effective.

Conclusions:

• The ACT study provides an innovative model for academic-industry collaboration in MS research.
• This trial will enhance understanding of combination therapy's utility in RRMS.
• Findings will inform treatment strategies for RRMS patients with suboptimal response to first-line therapy.